Most drug or device launches today require a health economic valuation often in the form of a Health Technology Assessment (HTA) to satisfy payers that the new ‘technology’ is advantageous for the...
When someone uses the expression "you're comparing apples to oranges" they're really saying "Why are you trying to compare those things? You can't compare apples to oranges; they're just not the...
Two recent healthcare events supported by the One Nucleus biotech network, has nicely highlighted some of the challenges facing healthcare companies and investors that are looking to bring...
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month. Firstly how exciting the market is right now, with many productive collaborations...
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical...
In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation...
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...
Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the...
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem.
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting.
